《大行報告》中金下調石藥(01093.HK)目標價至11.7元 評級「跑贏行業」
中金發表研究報告,指石藥集團(01093.HK)首季收入按年增16.9%至78.7億元人民幣(下同),純利按年跌4.6%至14億元,經常性淨利潤按年增10.3%至15.4億元;收入及經常性淨利潤均符合該行預期,由於金融資產公允價值損失1.33億元,其首季純利遜預期。
該行表示,看好集團核心產品銷量增長,將集團今明兩年收入預測各上調3%,但鑑於價格壓力及研發支出增加,該行大致上維持對集團的盈利預測,並將其目標價下調7%至11.7港元,相當於預測今明兩年市盈率19.6倍及18倍,有49%上行空間,維持「跑贏行業」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.